Company profile: Halia Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for inflammatory and neurodegenerative disorders, including HT-6184, a novel NEK7/NLRP3 inhibitor in Phase II for lower-risk myelodysplastic syndromes and post-procedure diagnostic biomarkers of inflammation and pain. Pipeline includes NEK7 inhibitors to block NLRP3 inflammasome assembly and LRRK2 inhibitors for diseases such as Parkinson's and Alzheimer's.
Products and services
- HT-6184: A clinical-stage NEK7/NLRP3 inhibitor that specifically targets chronic inflammatory disorders and neurodegenerative diseases, currently in Phase II for LR-MDS and post-procedure diagnostic biomarkers of inflammation and pain
- LRRK2 Inhibitors: Discovery-stage therapies engineered to target the LRRK2 protein for treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's
- NEK7 Inhibitors: Mechanism-specific drug candidates that target NEK7 to inhibit NLRP3 inflammasome assembly, aimed at treating various inflammatory diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Halia Therapeutics
Omeros
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for inflammation and central nervous system disorders, including MASP-2 antibodies (narsoplimab, OMS1029) for lectin pathway diseases such as TA-TMA and lupus nephritis; MASP-3 antibody (OMS906) for PNH; small-molecule PDE7 (OMS527) and PPARγ (OMS405) candidates for addiction; and GPR174 inhibitors for cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omeros company profile →
Merus Labs
HQ: Canada
Website
- Description: Provider of pharmaceutical products across broad therapeutic classes, leveraging an opportunistic product acquisition strategy to source acquisition candidates and access targets not available to other players.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Merus Labs company profile →
TiGenix
HQ: Belgium
Website
- Description: Provider of innovative local regenerative medicine treatments for damaged and osteoarthritic joints, focusing on research and development of durable therapies validated through controlled clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TiGenix company profile →
PD-Rx Pharmaceuticals
HQ: United States
Website
- Description: Provider of quality products and personal customer service to the healthcare industry.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PD-Rx Pharmaceuticals company profile →
Farmalider
HQ: Spain
Website
- Description: Provider of development, registration, licensing and manufacturing of generic pharmaceuticals, with two plants producing prescription, OTC and dietary supplement products in liquid, granulated and solid oral forms. Specializes in pain management, leading in ibuprofen and paracetamol in Spain. Services include formulation R&D, clinical trial batches, registration documentation, pharmacovigilance, and supply of generics in growing European markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Farmalider company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Halia Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Halia Therapeutics
2.2 - Growth funds investing in similar companies to Halia Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Halia Therapeutics
4.2 - Public trading comparable groups for Halia Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →